At this crisis point in history - what could possibly create these rare and extraordinary gains?

An Arizona multi-millionaire's revolutionary initiative is 
helping average Americans  find quick and lasting stock market success.

Since the Coronavirus came into our lives this slice of the stock market has given ordinary people the chance to multiply their money by 96% in 21 days on JP Morgan.


Stocks  | July 8, 2019

The following stocks all have a current price under $10, a very bullish market sentiment, and an average analysts ranking of strong buy. Analysts also expect each stock to rise considerably over the next 12 months.

CynergisTek (CTEK)

CynergisTek (CTEK), a top-ranked cybersecurity and consulting firm, has risen 21.25% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

Stock Score Report, InvestorsObserver’s proprietary scoring system, gives CTEK stock a score of 79 out of a possible 100. That score is mainly influenced by a long-term technical score of 90. CTEK’s score also includes a short-term technical score of 76. The fundamental score for CTEK is 70. In addition to the average rating from Wall Street analysts, CTEK stock has a mean target price of $7.32. This means analysts expect the stock to increase 50.93% over the next 12 months.

Global Ship Lease (GSL)

Global Ship Lease (GSL), a company that owns and charters out containerships, is down -19.78% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

Stock Score Report, InvestorsObserver’s proprietary scoring system, gives GSL stock a score of 83 out of a possible 100. That score is mainly influenced by a fundamental score of 100. In addition to the average rating from Wall Street analysts, GSL stock has a mean target price of $16.00. This means analysts expect the stock to gain 96.32% over the next 12 months. GSL’s score also includes a short-term technical score of 78. The long-term technical score for GSL is 72.

Minerva Neurosciences (NERV)

Minerva Neurosciences (NERV), a clinical-stage biopharmaceutical company, is down -19.77% over the last 12 months, and the average rating from Wall Street analysts is a Strong Buy.

Stock Score Report, InvestorsObserver’s proprietary scoring system, gives NERV stock a score of 76 out of a possible 100. That score is primarily influenced by a fundamental score of 89. In addition to the average rating from Wall Street analysts, NERV stock has a mean target price of $20.00. This means analysts expect the stock to add 189.86%over the next 12 months. NERV’s score also includes a long-term technical score of 73. The short-term technical score for NERV is 67.


A revolutionary initiative is helping average Americans find quick and lasting stock market success.

275% in one week on XLF - an index fund for the financial sector. Even 583%, in 7 days on XHB… an ETF of homebuilding companies in the S&P 500. 


{"email":"Email address invalid","url":"Website address invalid","required":"Required field missing"}

You might also like


Stocks | January 28

Stocks | January 28

Investing, Stocks | January 27

Investing | January 27